Dr. Maria Eugenia Suarez-Almazor, MD

Dr. Suarez-Almazor practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Suarez-Almazor's NPI, 1952341810, was assigned on June 8, 2006. Dr. Suarez-Almazor graduated from University of Buenos Aires in 1979. Dr. Suarez-Almazor holds Texas license M3399.

Dr. Suarez-Almazor's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Suarez-Almazor's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Suarez-Almazor practices. Vendor and product names are available with a free account.

Rheumatology is Dr. Suarez-Almazor's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dr. Suarez-Almazor is board certified in rheumatology by the American Board of Internal Medicine. Dmand AI has Dr. Suarez-Almazor's licenses on file in 2 states: Texas and Florida.

Dmand AI lists arteritis, arthritis, fluid in a joint, gout, joint arthropathy, joint pain, osteoporosis and rheumatoid arthritis among the conditions Dr. Suarez-Almazor treats.

CMS data shows 154 Medicare services from Dr. Suarez-Almazor across 5 procedure codes in 2024, for 142 Medicare patients. Medicare paid $12,521 for them.

CMS counts 142 Medicare patients who saw Dr. Suarez-Almazor in 2024. The largest group is 65 to 74, with 66 patients. 75% of them have high blood pressure, and 73% have high cholesterol. 8% are also on Medicaid. Their average risk score is 2.61, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Suarez-Almazor's median patient age at 72, with 85% women.

In 2024, Dr. Suarez-Almazor wrote 184 Medicare Part D claims for 35 patients. 73% of them were for generic drugs. CMS names the drug for 116 of them, across 6 drugs with 11 or more claims each, at $83,133 in total drug cost. In 2023, CMS named 104 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Suarez-Almazor for performance year 2024, reported as part of a group. Dr. Suarez-Almazor accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Suarez-Almazor as offering telehealth.

Dmand AI links 298 papers to Dr. Suarez-Almazor, published from 2006 to 2025. 2019 was the busiest year, with 16. The most frequent topics are Arthritis, Rheumatoid, Antirheumatic Agents and Osteoarthritis, Knee. Dr. Suarez-Almazor has published most often in J Rheumatol. Dr. Suarez-Almazor's most frequent co-authors are Vibeke Strand, MD, Sharon M. Giordano, MD, MPH and Jasvinder Singh.

Dmand AI links Dr. Suarez-Almazor to 4 clinical trials. Conditions studied include Diabetes Mellitus, Type 2, Liver Failure and Osteoarthritis. M.D. Anderson Cancer Center sponsors the most, 4.

CMS Open Payments shows 78 general payments to Dr. Suarez-Almazor from 13 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 79% of the total. Pfizer Inc. paid the most, $27,619. It also lists 2 research payments totaling $13,770 from 2021 to 2022.

Dmand AI lists 1 award for Dr. Suarez-Almazor.

Dr. Suarez-Almazor graduated from University of Buenos Aires in 1979. Dr. Suarez-Almazor is a member of ACR.

Dr. Suarez-Almazor is in network with 3 carriers, including Aetna, Blue Cross Blue Shield of Michigan and CMS Medicare. HMO plans come from the most carriers, 2. Check the plan with the practice before a visit.